Timeline of incretin therapeutics: difference between revisions
Diff·revision 17 → 18·01:22, 22 Jun 2025
Difference between revision 17 and revision 18 of Timeline of incretin therapeutics. 3 lines changed; the page grew by 468 bytes.
| Revision 17 — 21:02, 28 May 2025 BaselineBex (talk) expand §Physiology 3,992 bytes +38 | Revision 18 — 01:22, 22 Jun 2025 OralSemaOswin (talk) expand §Second generation and beyond 4,460 bytes +468 | ||
|---|---|---|---|
| 52 | The 2021 and 2023 publications are the ones that moved the field from diabetes into obesity medicine at scale, and the 2023 and 2024 outcome trials are what distinguish these agents from weight-loss interventions without outcome evidence.{{r|ada2024}} | 52 | The 2021 and 2023 publications are the ones that moved the field from diabetes into obesity medicine at scale, and the 2023 and 2024 outcome trials are what distinguish these agents from weight-loss interventions without outcome evidence.{{r|ada2024}} |
| 53 | 53 | ||
| + | 54 | Compounds beyond this point — [[Triple agonist|triple agonists]], [[CagriSema|combinations]], [[Orforglipron|oral small molecules]] — are investigational, and this timeline will require revision as their programmes report.{{r|drucker2018}} Material sold under those names outside licensed supply is unapproved.{{r|usp1503}} | |
| + | 55 | ||
| 54 | == References == | 56 | == References == |
| 55 | {{reflist}} | 57 | {{reflist}} |
| ⋮ | ⋮ | ||
| 57 | <ref name="holst2007">Holst JJ. "The physiology of glucagon-like peptide 1." ''Physiological Reviews'' 87(4):1409–1439 (2007). PMID 17928588.</ref> | 59 | <ref name="holst2007">Holst JJ. "The physiology of glucagon-like peptide 1." ''Physiological Reviews'' 87(4):1409–1439 (2007). PMID 17928588.</ref> |
| 58 | <ref name="ada2024">American Diabetes Association. "Standards of Care in Diabetes." ''Diabetes Care'' 47(Suppl 1) (2024).</ref> | 60 | <ref name="ada2024">American Diabetes Association. "Standards of Care in Diabetes." ''Diabetes Care'' 47(Suppl 1) (2024).</ref> |
| + | 61 | <ref name="usp1503">United States Pharmacopeia, General Chapter <1503>, ''Quality Attributes of Synthetic Peptide Drug Substances''.</ref> | |
| 59 | 62 | ||
| 60 | == See also == | 63 | == See also == |